/

Società

Ma

Non verificato

MaaT Pharma

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

42 comunicati stampa

Guarda tutti i comunicati

26/05/2026

Pubblico Esercizio/Vendita al dettaglio

Eventi

Mercato azionario

Scienza

Medicina - Varie

Biotecnologia

Salute

Farmaceutica

Oncologia

MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026

Fonte

Emittente

1.00

0

20/05/2026

Oncologia

Salute

Sanità

Medicina - Varie

Scienza

Farmaceutica

Industria

MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease

Fonte

Emittente

1.00

0

01/04/2026

Industria

Eventi

Scienza

Oncologia

Sanità

Salute

Medicina - Varie

MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal

Fonte

Emittente

1.00

0

31/03/2026

Eventi

Mercato azionario

Biotecnologia

Farmaceutica

Salute

Oncologia

MaaT Pharma Announces 2025 Annual Results and Provides Business Updates

Fonte

Emittente

1.00

0

23/03/2026

Eventi

Biotecnologia

Sanità

Salute

Medicina - Varie

Oncologia

MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation

Fonte

Emittente

1.00

0

09/03/2026

Medicina - Varie

Attrezzature medico-sanitarie

Salute

Farmaceutica

Oncologia

MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management

Fonte

Emittente

1.00

0

20/01/2026

Scienza

Medicina - Varie

Sanità

Salute

Farmaceutica

Oncologia

Industria

MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis

Fonte

Emittente

1.00

0

08/12/2025

Industria

Eventi

Oncologia

Salute

Scienza

Sanità

Medicina - Varie

MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival

Fonte

Emittente

1.00

0

05/11/2025

Scienza

Medicina - Varie

Biotecnologia

Sanità

Salute

Oncologia

Industria

MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034

Fonte

Emittente

1.00

0

04/11/2025

Biotecnologia

Farmaceutica

Salute

Oncologia

Eventi

Fiere

Mercato azionario

MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0